Simulations Plus Inc (SLP)

Simulations Plus Reports Third Quarter Fiscal 2026 Financial ResultsJuly 9, 2026 4:05 PM
Business Wire Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its third quarter fiscal 2026, ended May 31, 2026. Third Quarter 2026 Financial Highlights (as compared to third quarter 2025) Total revenue increased 7% to $21.9 million Software revenue was flat at $12.6 million, representing 58% of total revenue Services revenue increased 20% to $9.3 million, representing 42% of total revenue Gross profit was $15.1 million and gross margin was 69%, compared to $13.0 million and 64% Net income of $3.6 million and diluted earnings per share of $0.18, compared to net loss of $67.3 million and diluted losses per share of $3.35 Adjusted EBITDA of $7.9 million, representing 36% of total revenue, compared to $7.4 million, representing 37% of total revenue Adjusted net income of $6.1 million and adjusted diluted EPS of $0.30 compared to adjusted net income of $9.0 million and adjusted diluted EPS of $0.45 Nine Months 2026 Financial Highlights (as compared to nine months 2025) Total revenue increased 5% to $64.6 million Software revenue decreased 2% to $36.1 million, representing 56% of total revenue Services revenue increased 14% to $28.5 million, representing 44% of total revenue Gross profit was $42.2 million and gross margin was 65%, compared to $36.4 million and 59% Net income of $8.8 million and diluted earnings per share of $0.43, compared to net loss of $64.0 million and diluted losses per share of $3.19 Adjusted EBITDA of $20.2 million, representing 31% of total revenue, compared to $18.5 million, representing 30% of total revenue Adjusted net income of $15.7 million and adjusted diluted EPS of $0.78, compared to $18.7 million and adjusted diluted EPS of $0.93 Management Commentary “We delivered solid third quarter results, with revenue increasing 7%, highlighted by strength in our services revenue, which grew 20%, while software revenue was flat year over year,” said Shawn O'Connor, Chief Executive Officer of Simulations Plus. “Our performance reflects the resilience of our business model and the value our solutions provide to clients across the drug development lifecycle.” “Subsequent to quarter end, on June 15, 2026, we entered into a definitive merger agreement to be acquired by affiliates of Altaris, LLC (“Altaris”). We believe the transaction better positions Simulations Plus to further advance its scientific leadership and expand the impact of our model-informed and AI-enabled solutions. As we move toward the expected closing in the fourth quarter of calendar 2026, we remain focused on delivering for our clients and executing at a high level throughout this transition.” Non-GAAP Financial Measures This press release contains “non-GAAP financial measures,” which are measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”). A further explanation and reconciliation of these non-GAAP financial measures is included below and in the financial tables in this release. The Company believes that the non-GAAP financial measures presented facilitate an understanding of operating performance and provide a meaningful comparison of its results between periods. The Company’s management uses non-GAAP financial measures to, among other things, evaluate its ongoing operations in relation to historical results, for internal planning and forecasting purposes, and in the calculation of performance-based compensation. Adjusted EBITDA and Adjusted Diluted EPS represent measures that we believe are customarily used by investors and analysts to evaluate the financial performance of companies in addition to the GAAP measures that we present. Our management also believes that these measures are useful in evaluating our core operating results. However, Adjusted EBITDA and Adjusted Diluted EPS are not measures of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income, operating income, or diluted EPS as indicators of our operating performance or to net cash provided by operating activities as a measure of our liquidity. We believe the Company’s Adjusted EBITDA and Adjusted Diluted EPS measures provide information that is directly comparable to that provided by other peer companies in our industry, but other companies may calculate non-GAAP financial results differently, particularly related to nonrecurring, unusual items. Please note that the Company has not reconciled the adjusted EBITDA or adjusted diluted earnings per share forward-looking guidance included in this press release to the most directly comparable GAAP measures because this cannot be done without unreasonable effort due to the variability and low visibility with respect to costs related to acquisitions, financings, and employee stock compensation programs, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results. Adjusted EBITDA Adjusted EBITDA represents net income excluding the effect of interest expense (income), provision (benefit) for income taxes, depreciation and amortization, equity-based compensation expense, loss (gain) on currency exchange, impairment charges, change in fair value of contingent consideration, reorganization expense, acquisition and integration expense, and other items not indicative of our ongoing operating performance. Adjusted Net Income and Adjusted Diluted EPS Adjusted net income and adjusted diluted earnings per share exclude the effect of amortization, equity-based compensation expense, loss (gain) on currency exchange, impairment charges, change in fair value of contingent consideration, reorganization expense, acquisition and integration expense, and other items not indicative of our ongoing operating performance as well as the income tax provision adjustment for such charges. The Company excludes the above items because they are outside of the Company’s normal operations and/or, in certain cases, are difficult to forecast accurately. About Simulations Plus, Inc. Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. For more information, visit www.simulations-plus.com. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “will”, “can”, “expect,” “anticipate,” and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions, or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward-looking statements include but are not limited to statements regarding the effects of the definitive merger agreement, the anticipated closing date, and our fiscal year 2026 guidance,. These forward-looking statements are based on current assumptions and expectations that involve risks and uncertainties that could cause the actual results to differ materially from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our internal operational structure, our ability to maintain our competitive advantages and commercialize AI and cloud-enabled solutions, evolving regulatory and data privacy standards governing AI technologies, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual, and current reports and filed with the U.S. Securities and Exchange Commission.   SIMULATIONS PLUS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(Unaudited)       Three Months Ended   Nine Months Ended (in thousands, except per common share and common share data)   May 31, 2026   May 31, 2025   May 31, 2026   May 31, 2025 Revenues                 Software   $ 12,608     $ 12,615     $ 36,126     $ 36,814   Services     9,278       7,748       28,472       24,905   Total revenues     21,886       20,363       64,598       61,719   Cost of revenues                 Software     1,513       2,540       4,573       7,765   Services     5,246       4,791       17,864       17,577   Total cost of revenues     6,759       7,331       22,437       25,342   Gross profit     15,127       13,032       42,161       36,377   Operating expenses                 Research and development     3,406       1,216       9,856       5,207   Sales and marketing     2,538       2,680       8,647       9,248   General and administrative     4,684       6,141       12,816       16,089   Impairments     —       77,221       —       77,221   Total operating expenses     10,628       87,258       31,319       107,765   Income (loss) from operations     4,499       (74,226 )     10,842       (71,388 ) Other income, net     307       182       820       1,122                     Income (loss) before income taxes     4,806       (74,044 )     11,662       (70,266 ) Income tax (expense) benefit     (1,231 )     6,727       (2,876 )     6,229   Net income (loss)   $ 3,575     $ (67,317 )   $ 8,786     $ (64,037 )                   Earnings per share                 Basic   $ 0.18     $ (3.35 )   $ 0.44     $ (3.19 ) Diluted   $ 0.18     $ (3.35 )   $ 0.43     $ (3.19 )                   Weighted-average common shares outstanding                 Basic     20,209       20,113       20,170       20,092   Diluted     20,239       20,113       20,233       20,092                     Other comprehensive income (loss), net of tax                 Foreign currency translation adjustments     10       41       15       (27 ) Unrealized (losses) gains on available-for-sale securities     (8 )     —       (14 )     4   Comprehensive income (loss)   $ 3,577     $ (67,276 )   $ 8,787     $ (64,060 )   SIMULATIONS PLUS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited) (in thousands, except per common share and common share data)   May 31, 2026   August 31, 2025 ASSETS         Current assets         Cash and cash equivalents   $ 35,324     $ 30,853   Accounts receivable, net of allowance for credit losses of $59 and $187     17,202       9,717   Prepaid income taxes     263       1,777   Prepaid expenses and other current assets     7,670       7,702   Short-term investments     14,666       1,500   Total current assets     75,125       51,549   Long-term assets         Capitalized computer software development costs, net of accumulated amortization of $24,187 and $21,863     11,203       11,117   Property and equipment, net     513       880   Operating lease right-of-use assets     395       407   Intellectual property, net of accumulated amortization of $9,822 and $9,021     5,396       6,197   Other intangible assets, net of accumulated amortization of $5,127 and $4,399     11,074       11,896   Goodwill     43,717       43,717   Deferred tax assets, net     4,168       4,774   Other assets     1,385       1,399   Total assets   $ 152,976     $ 131,936   LIABILITIES AND SHAREHOLDERS' EQUITY         Current liabilities         Accounts payable   $ 2,234     $ 470   Accrued compensation     4,888       2,010   Accrued expenses     1,054       1,343   Operating lease liability - current portion     112       206   Deferred revenue     5,278       2,696   Total current liabilities     13,566       6,725   Long-term liabilities         Operating lease liability - net of current portion     375       410   Total liabilities     13,941       7,135   Commitments and contingencies         Shareholders' equity         Preferred stock, $0.001 par value — 10,000,000 shares authorized; no shares issued and outstanding   $ —     $ —   Common stock, $0.001 par value; 50,000,000 shares authorized, 20,216,438 and 20,137,480 shares issued and outstanding as of May 31, 2026, and August 31, 2025     20       20   Additional paid-in capital     164,863       159,416   Accumulated deficit     (25,578 )     (34,364 ) Accumulated other comprehensive loss     (270 )     (271 ) Total shareholders' equity     139,035       124,801   Total liabilities and shareholders' equity   $ 152,976       131,936     SIMULATIONS PLUS, INC.
Reconciliation of Adjusted EBITDA to Net Income (loss) (1)
(Unaudited)     Three months ended   Nine months ended (in thousands) May 31,
2026   May 31,
2025   May 31,
2026   May 31,
2025 Net income (loss) $ 3,575     $ (67,317 )   $ 8,786     $ (64,037 ) Excluding:               Interest income and expense, net   (344 )     (170 )     (899 )     (483 ) Provision for income taxes   1,231       (6,727 )     2,876       (6,229 ) Depreciation and amortization   1,368       2,318       4,261       6,857   Stock-based compensation   1,557       1,279       4,525       4,425   Loss on currency exchange   43       (35 )     85       (22 ) Impairments   —       77,221       —       77,221   (Income) loss from disposal of fixed assets   (6 )     23       (6 )     23   Change in value of contingent consideration   —       —       —       (640 ) Reorganization expense   4       845       4       1,260   Mergers & Acquisitions expense   462       —       527       133   Adjusted EBITDA $ 7,890     $ 7,437     $ 20,159     $ 18,508     (1) Numbers may not add due to rounding   SIMULATIONS PLUS, INC.
Reconciliation of Adjusted Diluted EPS to Diluted EPS (1)
(Unaudited)     Three months ended   Nine months ended (in thousands, except Diluted EPS and Adjusted Diluted EPS) May 31,
2026   May 31,
2025   May 31,
2026   May 31,
2025 Net income (loss) $ 3,575     $ (67,317 )   $ 8,786     $ (64,037 ) Excluding:               Amortization   1,340       2,165       4,059       6,425   Stock-based compensation   1,557       1,279       4,525       4,425   (Gain) loss on currency exchange   43       (35 )     85       (22 ) Mergers & Acquisitions expense   462       —       527       133   Change in value of contingent consideration   —       —       —       (640 ) Reorganization expense   4       845       4       1,260   Impairments   —       77,221       —       77,221   (Income) loss from disposal of fixed assets   (6 )     23       (6 )     23   Tax effect on above adjustments   (877 )     (5,153 )     (2,267 )     (6,119 ) Adjusted Net income $ 6,098     $ 9,028     $ 15,713     $ 18,669   Weighted-avg. common shares outstanding:               Diluted weighted-avg. common shares outstanding   20,239       20,113       20,233       20,092                   Diluted EPS $ 0.18     $ (3.35 )   $ 0.43     $ (3.19 ) Adjusted Diluted EPS $ 0.30     $ 0.45     $ 0.78     $ 0.93     (1) Numbers may not add due to rounding   View source version on businesswire.com: https://www.businesswire.com/news/home/20260709321948/en/ Investor Relations Contact:
Lisa Fortuna
Financial Profiles
310-622-8251
slp@finprofiles.com Original: Simulations Plus Reports Third Quarter Fiscal 2026 Financial Results

Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent ToolkitJune 23, 2026 9:15 AM
Business Wire New capabilities connect AI agents, scientific literature, and validated computational engines to accelerate model-informed drug development Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that helps advance biopharma innovation, today announced it is building the agentic layer of Composer, its AI-native platform for model-informed drug development, using the NVIDIA BioNeMo Agent Toolkit. The initiative expands the companies’ collaboration announced in May 2026, extending their work in GPU-accelerated simulation and AI-assisted modeling workflows into agentic drug development. Together, the companies are combining AI reasoning, scientific literature, validated computational engines, and scalable compute within a scientific workflow. The announcement coincides with NVIDIA’s introduction of the BioNeMo Agent Toolkit at the BIO International Convention. The integration is initially focused on two areas: Grounding scientific reasoning in trusted evidence Composer agents are expected to leverage NVIDIA Nemotron™ Parse to extract and structure information from scientific literature, enabling agents to retrieve relevant evidence while maintaining provenance back to the original source. Researchers can trace recommendations and conclusions to the supporting literature and data. Accelerating quantitative systems pharmacology at scale The companies are together advancing nvQSP, a collaborative development initiative focused on CUDA-optimized ordinary differential equation (ODE) solvers for quantitative systems pharmacology (QSP). By accelerating computationally intensive simulations on NVIDIA accelerated computing infrastructure, nvQSP enables scientists to explore larger parameter spaces, evaluate more hypotheses, and iterate more rapidly across complex biological systems. nvQSP builds on the companies’ previously announced work to accelerate computationally intensive QSP workflows using GPU-optimized simulation technology. These capabilities are being incorporated into Composer, allowing agents to coordinate scientific workflows while remaining rooted in validated computational engines and source-based evidence. “AI can help scientists explore more possibilities, but in drug development those insights must remain reproducible, explainable, and grounded in validated science,” said Erik Guffrey, Co-Chief Product and Technology Officer of Simulations Plus. “By combining the NVIDIA BioNeMo Agent Toolkit with our scientific engines, we’re building agents that seek to accelerate scientific work while preserving the rigor required for critical development decisions.” The initiative reflects Simulations Plus’ strategy to connect AI reasoning, scientific knowledge, and validated computational engines within a unified environment for model-informed drug development. “We believe agentic AI represents an important evolution in how scientists interact with models, data, and scientific knowledge,” said Shawn O’Connor, Chief Executive Officer of Simulations Plus. “Our goal is to help researchers move from question to insight more efficiently while keeping validated science at the center of decision-making.” About Simulations Plus, Inc. Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. For more information, visit www.simulations-plus.com. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “will”, “can”, “believe”, “expect,” “anticipate” and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward-looking statements in this press release include, but are not limited to, statements regarding: the development and incorporation of agentic AI capabilities into the Company's Composer platform; the anticipated benefits, functionality, performance, and availability of Composer agents and related technologies; the use of the NVIDIA BioNeMo Agent Toolkit and NVIDIA technologies within the Company's products and workflows; the advancement and expected capabilities of nvQSP and GPU-accelerated quantitative systems pharmacology workflows; the ability of AI-enabled technologies to accelerate scientific workflows, improve research productivity, enhance model-informed drug development, or generate actionable insights; the anticipated benefits of the collaboration between Simulations Plus and NVIDIA; and the Company's strategic plans, objectives, and expectations regarding AI, computational modeling, and drug development technologies. Factors that could cause or contribute to such differences include, but are not limited to: our ability to successfully develop, integrate, and commercialize new technologies, including AI-enabled products and capabilities; customer acceptance and adoption of new software products, enhancements, and services; our ability to maintain and strengthen our competitive position; our reliance on third-party technology providers, platforms, and infrastructure; the availability, performance, and cost of computing resources; our ability to attract, retain, and develop qualified personnel; changes in the pharmaceutical, biotechnology, and healthcare industries; regulatory, legal, and compliance developments relating to artificial intelligence and other technologies; general economic, business, and market conditions; and our ability to finance growth initiatives. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. View source version on businesswire.com: https://www.businesswire.com/news/home/20260623040671/en/ Financial Profiles
Lisa Fortuna
310-622-8251
slp@finprofiles.com Original: Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit

Simulations Plus, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – SLPJune 18, 2026 4:29 PM
Business WireThe DJS Law Group announces that it is investigating claims on behalf of investors of Simulations Plus, Inc. (“Simulations Plus” or “the Company”) (NASDAQ: SLP) violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.View source version on businesswire.com: https://www.businesswire.com/news/home/20260618705742/en/David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com Original: Simulations Plus, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – SLP

Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor ConferenceMay 21, 2026 4:05 PM
Business Wire Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the 23rd Annual Craig-Hallum Institutional Investor Conference taking place in Minneapolis, Minnesota. Mr. O’Connor will host one-on-one meetings with institutional investors on Thursday, May 28, 2026. For more information about the events or questions about registration, interested parties should reach out to their contacts at Craig-Hallum. About Simulations Plus, Inc. Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. For more information, visit www.simulations-plus.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260521068107/en/ Financial Profiles
Lisa Fortuna
310-622-8251
slp@finprofiles.com Original: Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling WorkflowsMay 6, 2026 7:55 AM
Business Wire Combines validated scientific engines with accelerated computing and AI to enable more scalable, integrated modeling workflows across the drug development lifecycle Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle. The collaboration brings together Simulations Plus’ validated scientific engines across physiologically-based pharmacokinetics (PBPK), pharmacokinetics/pharmacodynamics (PK/PD), and quantitative systems pharmacology (QSP) with NVIDIA AI infrastructure to accelerate and scale simulation cycles, parameter exploration, and virtual population studies. Together, these capabilities address two core constraints in model-informed drug development (MIDD): reducing manual, expertise-driven work and enabling large-scale exploration of model structures and parameters in parallel—shifting modeling from a sequential process to a more iterative, data-informed workflow operating at program-relevant timelines. NVIDIA contributes advanced computing infrastructure and expertise in accelerated inference and GPU-native optimization to improve simulation performance and enable interactive, AI-assisted workflows. NVIDIA also brings access to its life sciences ecosystem, including the NVIDIA BioNeMo platform and a global network of pharmaceutical partners, supporting broader engagement and adoption. “For three decades, Simulations Plus has helped pharmaceutical and biotechnology organizations apply modeling and simulation with confidence across drug development. Our collaboration with NVIDIA brings together validated science, accelerated computing, and AI capabilities in a way that expands what scientific teams are able to explore and accomplish,” said Shawn O’Connor, Chief Executive Officer of Simulations Plus. The collaboration is initially focused on three areas: Next-generation scientific engines Simulations Plus has begun developing GPU-optimized simulation capabilities for QSP and PK/PD applications, reducing runtimes and enabling broader exploration of complex biological systems. This enables scientists to evaluate a broader range of hypotheses without pre-pruning models, increasing confidence in model selection and supporting more robust program decisions. AI-assisted scientific workflows Simulations Plus is applying AI-assisted approaches, informed by NVIDIA’s expertise in accelerated inference and agentic AI, to support model construction, parameter fitting, diagnostics, and refinement—reducing manual effort and accelerating iteration from question to analysis. By reducing manual, time-intensive steps, these workflows will allow scientists to focus more on scientific interpretation and decision-making, significantly accelerating iteration cycles within drug development programs. Advancing quantitative systems pharmacology Simulations Plus is prioritizing QSP workflows—one of the most computationally demanding areas in drug development—by applying GPU acceleration and AI-assisted methods to improve simulation efficiency and expand practical use in pharmaceutical R&D. Current testing shows up to a 75% reduction in time required for end-to-end QSP modeling, enabling faster iteration and expanding the practical use of QSP within program timelines. As part of the collaboration, the companies plan to engage select pharmaceutical partners to evaluate these capabilities in real-world drug development workflows, with initial focus on high-complexity modeling use cases. “Scientific teams are asking for faster iteration, greater scale, and better ways to work across increasingly complex modeling problems. By combining our validated scientific engines with AI-assisted workflows and accelerated computing, we are extending our platform into a more integrated modeling ecosystem—where workflows scale across domains like QSP while remaining grounded in reproducible, scientifically validated outputs,” said Erik Guffrey, Co-Chief Product and Technology Officer of Simulations Plus. “Biopharma teams need platforms that can connect mechanistic modeling, AI, and high-performance simulation into workflows scientists can actually use. By bringing NVIDIA accelerated computing and AI infrastructure together with Simulations Plus’ deep expertise in model-informed drug development, we can help researchers run more complex models, explore larger design spaces, and move from insight to decision faster," said Anthony Costa, Director of Digital Biology and Health, NVIDIA. About Simulations Plus, Inc. Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. For more information, visit www.simulations-plus.com. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “will,” “can,” “expect,” “anticipate” and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new operational structure, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. View source version on businesswire.com: https://www.businesswire.com/news/home/20260506350085/en/ Financial Profiles
Lisa Fortuna
310-622-8251
slp@finprofiles.com Original: Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug ProductsApril 21, 2026 7:55 AM
Business Wire
Mechanistic modeling approach and experimental integration designed to improve early risk identification, strengthen regulatory confidence, and expand AI-enabled workflows connecting data to decision-making


Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded research collaboration with Lonza Group AG (“Lonza”), a leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry, and the U.S. Food and Drug Administration (FDA) to develop and validate a mechanistic, predictive framework for assessing the in vivo performance of amorphous solid dispersion (ASD) drug products.


“Complex oral formulations such as amorphous solid dispersions present significant scientific and regulatory challenges due to their sensitivity to physiological and manufacturing variables,” said Dr. Viera Lukacova, Chief Scientific Officer of Simulations Plus. “Through this funded collaboration, we aim to integrate advanced in vitro systems with mechanistic modeling to improve prediction of in vivo performance, support regulatory decision-making, and enable more efficient development pathways for these high-impact therapies that deliver faster dissolution and more drug absorption.”


Advancing Mechanistic, Model-Informed Approaches for Complex Products


ASDs are among the most powerful yet complex oral drug delivery systems, with performance influenced by factors such as food intake, gastric pH, formulation composition, and manufacturing processes. Current regulatory approaches often require multiple clinical bioequivalence (BE) studies, which can be resource-intensive while still carrying uncertainty.


The collaboration evaluates whether advanced in vitro dissolution systems—particularly those incorporating dynamic gastrointestinal physiology—combined with mechanistic physiologically based biopharmaceutics modeling (PBBM), can reliably predict key in vivo outcomes, including food effects and the impact of elevated gastric pH conditions.


By establishing and validating these predictive capabilities, the collaboration aims to provide a scientific foundation for reducing reliance on certain clinical BE studies while maintaining the rigor and transparency required by regulators.


Integrating Experimental and Mechanistic Modeling Expertise


The collaboration brings together complementary capabilities across experimental science and computational modeling.


Lonza will lead experimental work, including in vitro dissolution testing under fasted, fed, and elevated gastric pH conditions using advanced systems such as Controlled Transfer Dissolution (CTD), as well as the characterization and, where needed, manufacturing of ASD formulation variants.


Simulations Plus will lead the development and validation of in vitro–in vivo extrapolation (IVIVE) frameworks using its DDDPlus® and GastroPlus® platforms, translating experimental data into predictions of in vivo pharmacokinetics and supporting virtual bioequivalence assessments. At the same time, it creates new opportunities to extend these capabilities into grounded AI-enabled workflow environments, where data, mechanistic models, and simulation outputs will be more directly connected. The Company will also contribute to interpretation within a regulatory context, ensuring alignment with evolving expectations for model-informed drug development (MIDD).


Francois Ricard, Head of R&D, Lonza Advanced Synthesis, said, “This collaboration reflects Lonza’s commitment to advancing more predictive, science-driven approaches as the leader in the field of bioavailability enhancement. By combining advanced in vitro experimentation with mechanistic modeling, and working closely with Simulations Plus and the FDA, we aim to strengthen the scientific foundation that underpins regulatory decision-making for complex oral drug products. Ultimately, this type of collaboration should help accelerate development for our customers requiring bioequivalence during clinical development.”


Alignment with Regulatory Priorities and Industry Needs


This work is supported in part through FDA funding and includes ongoing engagement with FDA scientists to directly align with regulatory priorities to advance MIDD, modernize bioequivalence assessment for complex products, and reduce unnecessary reliance on human studies. By combining regulatory collaboration with open, non-proprietary data and validated methods based on real-world, FDA-approved ASD products, the initiative is intended to inform future regulatory approaches and support broader adoption of science-based alternatives.


“The industry is moving toward a future where decisions are informed earlier, with greater confidence and scientific transparency,” added Lukacova. “Our role is to ensure those decisions are grounded in validated science—while enabling more efficient ways to connect data, models, and insight.”


About Simulations Plus, Inc.


Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. For more information, visit www.simulations-plus.com.


Forward-Looking Statements


Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “will”, “can”, “expect,” “anticipate,” and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions, or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward-looking statements include but are not limited to statements regarding our fiscal year 2026 guidance, revenue growth, anticipated margins and profitability, demand to software and services, the impact of pricing actions, client spending levels, market conditions, the development, capabilities, regulatory acceptance, regulatory compliance and commercialization of AI-enabled and could-based solutions, the timing and content of product initiatives discussed at Investor Day, and our ability to execute our long-term strategic vision. These forward-looking statements are based on current assumptions and expectations that involve risks and uncertainties that could cause the actual results to differ materially from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our internal operational structure, our ability to maintain our competitive advantages and commercialize AI and cloud-enabled solutions, evolving regulatory and data privacy standards governing AI technologies, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual, and current reports and filed with the U.S. Securities and Exchange Commission. No regulatory authority has endorsed, approved, or validated the Company’s products, platforms, or AI-related approaches.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421564555/en/
Investor Relations Contact:

Lisa Fortuna

Financial Profiles

310-622-8251

slp@finprofiles.com


Original: Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

Simulations Plus Reports Second Quarter Fiscal 2026 Financial ResultsApril 9, 2026 4:05 PM
Business Wire
Revenue grew 8% with increases in both software and services


Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its second quarter fiscal 2026, ended February 28, 2026.


Second Quarter 2026 Financial Highlights (as compared to second quarter 2025)



Total revenue increased 8% to $24.3 million



Software revenue increased 9% to $14.6 million, representing 60% of total revenue



Services revenue increased 8% to $9.7 million, representing 40% of total revenue



Gross profit was $16.1 million and gross margin was 66%, compared to $13.1 million and 59%



Net income of $4.5 million and diluted earnings per share of $0.22, compared to net income of $3.1 million and diluted EPS of $0.15



Adjusted EBITDA of $8.7 million, representing 36% of total revenue, compared to $6.6 million, representing 29% of total revenue



Adjusted net income of $7.0 million and adjusted diluted EPS of $0.35 compared to adjusted net income of $6.2 million and adjusted diluted EPS of $0.31



Six Months 2026 Financial Highlights (as compared to six months 2025)



Total revenue increased 3% to $42.7 million



Software revenue decreased 3% to $23.5 million, representing 55% of total revenue



Services revenue increased 12% to $19.2 million, representing 45% of total revenue



Gross profit was $27.0 million and gross margin was 63%, compared to $23.3 million and 56%



Net income of $5.2 million and diluted earnings per share of $0.26, compared to net income of $3.3 million and diluted EPS of $0.16



Adjusted EBITDA of $12.3 million, representing 29% of total revenue, compared to $11.1 million, representing 27% of total revenue



Adjusted net income of $9.6 million and adjusted diluted EPS of $0.48, approximately equivalent to the same period last year



Management Commentary


“We delivered solid second quarter results, with revenue increasing by 8%,” said Shawn O’Connor, CEO of Simulations Plus. “Software growth was driven by strong performance in discovery and development solutions, partially offset by an anticipated decline in clinical operations software. We also saw continued success with new logo additions and client upsells. Services revenue growth was primarily driven by development solutions and bookings were strong during the quarter, resulting in an approximately 18% increase in backlog.”


“Market conditions remain favorable. Globally, ongoing most-favored-nation pricing agreements, reduced tariff threats, and an improving funding environment are benefiting our clients. In addition, we believe recent supplemental guidance on new approach methodologies is supporting increased client activity. We are seeing this reflected in strong software renewals, logo activity, and services bookings. Overall, we are pleased with our first-half fiscal 2026 performance and encouraged by the momentum we see across the business,” concluded O’Connor.


Fiscal 2026 Guidance


The Company is adjusting its guidance range for adjusted diluted EPS from a range of $1.03 - $1.10 to $0.75 - $0.85 to reflect an increase in the expected effective tax rate for fiscal 2026 from 12-14% to 23-25%. All other previously issued guidance metrics remain unchanged.




 






 






Fiscal 2026




Guidance








Revenue






 






$79M - $82M








Revenue growth






 






0 - 4%








Software mix






 






57 - 62%








Adjusted EBITDA margin






 






26 - 30%








Adjusted diluted EPS






 






$0.75 - $0.85







Webcast and Conference Call Details


Shawn O’Connor, Chief Executive Officer, and Will Frederick, Executive Vice President and Chief Financial Officer, will host a conference call and webcast today, April 9 at 5:00 p.m. Eastern Time to discuss the results and certain forward-looking information. The call may be accessed by registering here or by calling 1-877-451-6152 (domestic) or 1-201-389-0879 (international). The webcast can be accessed on the investor relations page of the Simulations Plus website https://www.simulations-plus.com/investorscorporate-profile/corporate-profile/ where it will also be available for replay approximately one hour following the call.


Non-GAAP Financial Measures


This press release contains “non-GAAP financial measures,” which are measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”).


A further explanation and reconciliation of these non-GAAP financial measures is included below and in the financial tables in this release.


The Company believes that the non-GAAP financial measures presented facilitate an understanding of operating performance and provide a meaningful comparison of its results between periods. The Company’s management uses non-GAAP financial measures to, among other things, evaluate its ongoing operations in relation to historical results, for internal planning and forecasting purposes, and in the calculation of performance-based compensation. Adjusted EBITDA and Adjusted Diluted EPS represent measures that we believe are customarily used by investors and analysts to evaluate the financial performance of companies in addition to the GAAP measures that we present. Our management also believes that these measures are useful in evaluating our core operating results. However, Adjusted EBITDA and Adjusted Diluted EPS are not measures of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income, operating income, or diluted EPS as indicators of our operating performance or to net cash provided by operating activities as a measure of our liquidity. We believe the Company’s Adjusted EBITDA and Adjusted Diluted EPS measures provide information that is directly comparable to that provided by other peer companies in our industry, but other companies may calculate non-GAAP financial results differently, particularly related to nonrecurring, unusual items.


Please note that the Company has not reconciled the adjusted EBITDA or adjusted diluted earnings per share forward-looking guidance included in this press release to the most directly comparable GAAP measures because this cannot be done without unreasonable effort due to the variability and low visibility with respect to costs related to acquisitions, financings, and employee stock compensation programs, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.


Adjusted EBITDA


Adjusted EBITDA represents net income excluding the effect of interest expense (income), provision (benefit) for income taxes, depreciation and amortization, equity-based compensation expense, loss (gain) on currency exchange, impairment charges, change in fair value of contingent consideration, reorganization expense, acquisition and integration expense, and other items not indicative of our ongoing operating performance.


Adjusted Net Income and Adjusted Diluted EPS


Adjusted net income and adjusted diluted earnings per share exclude the effect of amortization, equity-based compensation expense, loss (gain) on currency exchange, impairment charges, change in fair value of contingent consideration, reorganization expense, acquisition and integration expense, and other items not indicative of our ongoing operating performance as well as the income tax provision adjustment for such charges.


The Company excludes the above items because they are outside of the Company’s normal operations and/or, in certain cases, are difficult to forecast accurately.


About Simulations Plus, Inc.


Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. For more information, visit www.simulations-plus.com.


Forward-Looking Statements


Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “will,” “can,” “expect,” “anticipate,” and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions, or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward-looking statements include but are not limited to statements regarding our fiscal year 2026 guidance, revenue growth, anticipated margins and profitability, demand to software and services, the impact of pricing actions, client spending levels, market conditions, the development, capabilities, regulatory acceptance and commercialization of AI-enabled and cloud-based solutions, the timing and content of product initiatives discussed at Investor Day, and our ability to execute our long-term strategic vision. These forward-looking statements are based on current assumptions and expectations that involve risks and uncertainties that could cause the actual results to differ materially from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our internal operational structure, our ability to maintain our competitive advantages and commercialize AI and cloud-enabled solutions, evolving regulatory and data privacy standards governing AI technologies, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual, and current reports and filed with the U.S. Securities and Exchange Commission.




SIMULATIONS PLUS, INC.




CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME




(Unaudited)











 



(in thousands, except per common share and common share data)






 






Three Months Ended






 






Six Months Ended








 






February 28,




2026






 






February 28,




2025






 






February 28,




2026






 






February 28,




2025








Revenues






 






 






 






 






 






 






 






 








Software






 






$






14,635






 






 






$






13,484






 






 






$






23,518






 






 






$






24,199






 








Services






 






 






9,656






 






 






 






8,948






 






 






 






19,194






 






 






 






17,157






 








Total revenues






 






 






24,291






 






 






 






22,432






 






 






 






42,712






 






 






 






41,356






 








Cost of revenues






 






 






 






 






 






 






 






 








Software






 






 






1,648






 






 






 






2,587






 






 






 






3,060






 






 






 






5,225






 








Services






 






 






6,500






 






 






 






6,718






 






 






 






12,618






 






 






 






12,786






 








Total cost of revenues






 






 






8,148






 






 






 






9,305






 






 






 






15,678






 






 






 






18,011






 








Gross profit






 






 






16,143






 






 






 






13,127






 






 






 






27,034






 






 






 






23,345






 








Operating expenses






 






 






 






 






 






 






 






 








Research and development






 






 






3,470






 






 






 






2,143






 






 






 






6,450






 






 






 






3,991






 








Sales and marketing






 






 






2,930






 






 






 






3,717






 






 






 






6,109






 






 






 






6,568






 








General and administrative






 






 






4,113






 






 






 






4,555






 






 






 






8,132






 






 






 






9,948






 








Total operating expenses






 






 






10,513






 






 






 






10,415






 






 






 






20,691






 






 






 






20,507






 








Income from operations






 






 






5,630






 






 






 






2,712






 






 






 






6,343






 






 






 






2,838






 








Other income, net






 






 






256






 






 






 






796






 






 






 






513






 






 






 






940






 








 






 






 






 






 






 






 






 






 








Income before income taxes






 






 






5,886






 






 






 






3,508






 






 






 






6,856






 






 






 






3,778






 








Income tax expense






 






 






(1,351






)






 






 






(434






)






 






 






(1,645






)






 






 






(498






)








Net income






 






$






4,535






 






 






$






3,074






 






 






$






5,211






 






 






$






3,280






 








 






 






 






 






 






 






 






 






 








Earnings per share






 






 






 






 






 






 






 






 








Basic






 






$






0.22






 






 






$






0.15






 






 






$






0.26






 






 






$






0.16






 








Diluted






 






$






0.22






 






 






$






0.15






 






 






$






0.26






 






 






$






0.16






 








 






 






 






 






 






 






 






 






 








Weighted-average common shares outstanding






 






 






 






 






 






 






 






 








Basic






 






 






20,160






 






 






 






20,097






 






 






 






20,150






 






 






 






20,082






 








Diluted






 






 






20,243






 






 






 






20,277






 






 






 






20,232






 






 






 






20,262






 








 






 






 






 






 






 






 






 






 








Other comprehensive income (loss), net of tax






 






 






 






 






 






 






 






 








Foreign currency translation adjustments






 






 






11






 






 






 






(26






)






 






 






5






 






 






 






(68






)








Unrealized gains (losses) on available-for-sale securities






 






 






(6






)






 






 






—






 






 






 






(6






)






 






 






4






 








Comprehensive income






 






$






4,540






 






 






$






3,048






 






 






$






5,210






 






 






$






3,216






 









SIMULATIONS PLUS, INC.




CONDENSED CONSOLIDATED BALANCE SHEETS




(Unaudited)











 



(in thousands, except per common share and common share data)






 






February 28,




2026






 






August 31,




2025








ASSETS






 






 






 






 








Current assets






 






 






 






 








Cash and cash equivalents






 






$






25,727






 






 






$






30,853






 








Accounts receivable, net of allowance for credit losses of $73 and $187






 






 






18,170






 






 






 






9,717






 








Prepaid income taxes






 






 






669






 






 






 






1,777






 








Prepaid expenses and other current assets






 






 






6,885






 






 






 






7,702






 








Short-term investments






 






 






16,109






 






 






 






1,500






 








Total current assets






 






 






67,560






 






 






 






51,549






 








Long-term assets






 






 






 






 








Capitalized computer software development costs, net of accumulated amortization of $23,543 and $21,863






 






 






11,158






 






 






 






11,117






 








Property and equipment, net






 






 






752






 






 






 






880






 








Operating lease right-of-use assets






 






 






373






 






 






 






407






 








Intellectual property, net of accumulated amortization of $9,555 and $9,021






 






 






5,663






 






 






 






6,197






 








Other intangible assets, net of accumulated amortization of $4,904 and $4,399






 






 






11,327






 






 






 






11,896






 








Goodwill






 






 






43,717






 






 






 






43,717






 








Deferred tax assets, net






 






 






4,589






 






 






 






4,774






 








Other assets






 






 






1,345






 






 






 






1,399






 








Total assets






 






$






146,484






 






 






$






131,936






 








LIABILITIES AND SHAREHOLDERS' EQUITY






 






 






 






 








Current liabilities






 






 






 






 








Accounts payable






 






$






803






 






 






$






470






 








Accrued compensation






 






 






4,398






 






 






 






2,010






 








Accrued expenses






 






 






1,474






 






 






 






1,343






 








Operating lease liability - current portion






 






 






138






 






 






 






206






 








Deferred revenue






 






 






5,530






 






 






 






2,696






 








Total current liabilities






 






 






12,343






 






 






 






6,725






 








Long-term liabilities






 






 






 






 








Operating lease liability - net of current portion






 






 






370






 






 






 






410






 








Total liabilities






 






 






12,713






 






 






 






7,135






 








Commitments and contingencies






 






 






 






 








Shareholders' equity






 






 






 






 








Preferred stock, $0.001 par value — 10,000,000 shares authorized; no shares issued and outstanding






 






$






—






 






 






$






—






 








Common stock, $0.001 par value; 50,000,000 shares authorized, 20,205,482 and 20,137,480 shares issued and outstanding as of February 28, 2026, and August 31, 2025






 






 






20






 






 






 






20






 








Additional paid-in capital






 






 






163,176






 






 






 






159,416






 








Accumulated deficit






 






 






(29,153






)






 






 






(34,364






)








Accumulated other comprehensive loss






 






 






(272






)






 






 






(271






)








Total shareholders' equity






 






 






133,771






 






 






 






124,801






 








Total liabilities and shareholders' equity






 






$






146,484






 






 






 






131,936






 









SIMULATIONS PLUS, INC.




Reconciliation of Adjusted EBITDA to Net Income (1)




(Unaudited)










 



 






Three months ended






 






Six months ended








(in thousands)






February 28,




2026






 






February 28,




2025






 






February 28,




2026






 






February 28,




2025








Net income






$






4,535






 






 






$






3,074






 






 






$






5,211






 






 






$






3,280






 








Excluding:






 






 






 






 






 






 






 








Interest income and expense, net






 






(288






)






 






 






(154






)






 






 






(555






)






 






 






(313






)








Provision for income taxes






 






1,351






 






 






 






434






 






 






 






1,645






 






 






 






498






 








Depreciation and amortization






 






1,547






 






 






 






2,274






 






 






 






2,893






 






 






 






4,539






 








Stock-based compensation






 






1,503






 






 






 






1,557






 






 






 






2,968






 






 






 






3,146






 








Loss on currency exchange






 






32






 






 






 






(2






)






 






 






42






 






 






 






13






 








Change in value of contingent consideration






 






—






 






 






 






(640






)






 






 






—






 






 






 






(640






)








Reorganization expense






 






—






 






 






 






157






 






 






 






—






 






 






 






415






 








Mergers & Acquisitions expense






 






55






 






 






 






(122






)






 






 






65






 






 






 






133






 








Adjusted EBITDA






$






8,735






 






 






$






6,578






 






 






$






12,269






 






 






$






11,071






 






















 



(1) Numbers may not foot due to rounding









SIMULATIONS PLUS, INC.




Reconciliation of Adjusted Diluted EPS to Diluted EPS (1)




(Unaudited)










 



(in thousands, except Diluted EPS and Adjusted Diluted EPS)






Three months ended






 






Six months ended








February 28,




2026






 






February 28,




2025






 






February 28,




2026






 






February 28,




2025








Net income






$






4,535






 






 






$






3,074






 






 






$






5,211






 






 






$






3,280






 








Excluding:






 






 






 






 






 






 






 








Amortization






 






1,460






 






 






 






2,130






 






 






 






2,719






 






 






 






4,260






 








Stock-based compensation






 






1,503






 






 






 






1,557






 






 






 






2,968






 






 






 






3,146






 








(Gain) loss on currency exchange






 






32






 






 






 






(2






)






 






 






42






 






 






 






13






 








Mergers & Acquisitions expense






 






55






 






 






 






(122






)






 






 






65






 






 






 






133






 








Change in value of contingent consideration






 






—






 






 






 






(640






)






 






 






—






 






 






 






(640






)








Reorganization expense






 






—






 






 






 






157






 






 






 






—






 






 






 






415






 








Tax effect on above adjustments






 






(558






)






 






 






41






 






 






 






(1,390






)






 






 






(966






)








Adjusted Net income






$






7,027






 






 






$






6,195






 






 






$






9,615






 






 






$






9,641






 








Weighted-avg. common shares outstanding:






 






 






 






 






 






 






 








Diluted weighted-avg. common shares outstanding






 






20,243






 






 






 






20,277






 






 






 






20,232






 






 






 






20,262






 








 






 






 






 






 






 






 






 








Diluted EPS






$






0.22






 






 






$






0.15






 






 






$






0.26






 






 






$






0.16






 








Adjusted Diluted EPS






$






0.35






 






 






$






0.31






 






 






$






0.48






 






 






$






0.48






 






















 



(1) Numbers may not foot due to rounding







 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260409950592/en/
Investor Relations Contact:

Lisa Fortuna

Financial Profiles

310-622-8251

slp@finprofiles.com


Original: Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results